covid
Buscar en
Progresos de Obstetricia y Ginecología
Toda la web
Inicio Progresos de Obstetricia y Ginecología Detectar la depresión antes, durante y después de la gestación con el perfil ...
Información de la revista
Vol. 47. Núm. 1.
Páginas 27-35 (enero 2004)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 47. Núm. 1.
Páginas 27-35 (enero 2004)
Acceso a texto completo
Detectar la depresión antes, durante y después de la gestación con el perfil anímico del embarazo
Detecting depression before, during and after pregnancy with the pregnancy mood profile
Visitas
7242
D.M. Campagne
Autor para correspondencia
platon@ctv.es

Correspondencia: Clínica Bella Médica. Ctra. Nacional N-332. Altea. Alicante. España
Psicólogo. Departamento de Personalidad, Evaluación y Tratamiento Psicológicos. Universidad Nacional de Educación a Distancia. Madrid. Clínica Bella Médica. Altea. Alicante. España
Este artículo ha recibido
Información del artículo
Resumen
Bibliografía
Descargar PDF
Estadísticas
Resumen

Las depresiones anteparto y posparto son condiciones médicas nada excepcionales que afectan de forma negativa a madre e hijo, y necesitan ser detectadas lo antes posible para evitar o limitar el uso de tratamientos farmacológicos con posibles efectos colaterales. Sólo la depresión posparto tiene entidad clínica propia reconocida, aunque existen razones sólidas para que la depresión relacionada con la gestación, en todos sus estadios, se considere una enfermedad propia por las consecuencias posiblemente graves sobre madre e hijo.

El autor revisa los datos actuales que justifican una mayor atención por parte del tocólogo a la apariencia de síntomas depresivos desde los primeros momentos de la concepción y gestación. A tal fin ha propuesto un protocolo estadístico sencillo con que se confecciona un «perfil anímico del embarazo». Este perfil ayudaría en el tratamiento adecuado de la depresión anteparto y posparto y serviría como un preaviso de suicidio posparto.

Palabras clave:
Perfil anímico del embarazo
Depresión anteparto
Depresión posparto
Suicidio
Abstract

Antepartum and postpartum depression are common medical conditions which negatively affect mother and child and which should be detected as early as possible to avoid or limit the use of pharmacological treatments with possible side effects. Only postpartum depression has been given a proper clinical identity, although there is ample evidence to support the creation of a specific identity for pregnancy-related depression due to the possibly serious consequences for mother and child.

The author reviews the current evidence supporting the need for obstetricians to pay greater attention to signs of depression from the beginning of conception and pregnancy. To that purpose, a simple statistical protocol to determine a «pregnancy mood profile» is proposed. This profile would assist in managing antepartum and postpartum depression and would serve as a prealert for postpartum suicide.

Key words:
Pregnancy mood profile
Antepartum depression
Postpartum depression
Suicide
El Texto completo está disponible en PDF
Bibliografía
[1.]
US Preventive Services Task Force (2002) Screening for depression: recommendations and rationale.
Ann Intern Med, 136 (2002), pp. 760-764
[2.]
C. Ascaso, L. Garcia, P. Navarro, J. Aguado, J. Ojuel, M.J. Tarragona.
Prevalencia de la depresión posparto en las madres españolas.
Med Clin (Barc), 120 (2003), pp. 326-329
[3.]
L. Speroff, R.H. Glass, N.G. Kase.
Clinical gynecologic endocrinology and infertility.
1st Spanish ed, Waverly, (2000),
[4.]
S.M. Marcus, H.A. Flynn, F.C. Blow, K.L. Barry.
Depressive symptoms among pregnant women screened in obstetrics settings.
J Women’s Health, 12 (2003), pp. 373-380
[5.]
D.M. Campagne.
Psiconeuroendocrinología de la infertilidad.
Boletín SEF, 11 (2002), pp. 9-18
[6.]
D. Guerra, S. Golombok, A. Brewaeys, R. Cook, M.T. Giavazzi, A. Mantovani, et al.
Estudio europeo de familias de reproducción asistida.
Prog Obstet Ginecol, 41 (1998), pp. 283-293
[7.]
C. Rainey.
Sexual dysfunction in people being treated for depression.
APA 52nd Conference. Philadelphia, (2000),
[8.]
S.S. Girdler, P.A. Straneva, K.C. Light, C.A. Pedersen, A.L. Morrow.
Allopregnanolone levels and reactivity to mental stress in premenstrual dysphoric disorder.
Biol Psychiatry, 49 (2001), pp. 788-797
[9.]
S.M. Marcus, K.L. Barry, H.A. Flynn, R. Tandon, J.F. Greden.
Treatment guidelines for depression in pregnancy.
Int J Gynecol Obstet, 72 (2001), pp. 61-70
[10.]
D.M. Campagne.
Screening depressive patients in pregnancy with the pregnancy mood profile.
J Reprod Med, 48 (2003), pp. 817
[11.]
American Psychiatric Association.
Diagnostic and Statistical Manual of Mental Disorders (DSM-IV).
APA, (1994),
[12.]
K.L. Wisner, B.L. Parry, C.M. Piontek.
Postpartum depression.
N Engl J Med, 447 (2002), pp. 18
[13.]
J. Evans, J. Heron, H. Francomb, S. Oke, J. Golding.
Cohort study of depressed mood during pregnancy and after childbirth.
Bmj, 323 (2001), pp. 257-260
[14.]
S.H. Kennedy, S.E. Dickens, B.S. Eisfeld, R.M. Bagby.
Sexual dysfunction before antidepressant therapy in major depression.
J Affect Disord, 56 (1999), pp. 201-208
[15.]
A.J. Rothschild.
New directions in the treatment of antidepressant-induced sexual disfunction.
Clin Ther, 22 (2000), pp. 42-57
[16.]
S.H. Kennedy, B.S. Eisfeld, S.E. Dickens, J.R. Bacchiochi, R.M. Bagby.
Antidepressant-induced sexual dysfunction during treatment with moclobemide, paroxetine, sertraline, and venlafaxine.
J Clin Psychiatry, 61 (2000), pp. 276-281
[17.]
G.B. Bovasso.
Cannabis abuse as a risk factor for depressive symptoms.
Am J Psychiatry, 158 (2001), pp. 2033-2037
[18.]
M. Cunningham, L.H. Zayas.
Reducing depression in pregnancy: designing multimodal interventions.
Soc Work, 47 (2002), pp. 114-123
[19.]
T.G. O’Connor, J. Heron, J. Golding, M. Beveridge, V. Glover.
Maternal antenatal anxiety and children’s behavioural/emotional problems at 4 years: Report from the Avon Longitudinal Study of Parents and Children.
Br J Psychiatry, 180 (2002), pp. 502-508
[20.]
L. Allister, B.M. Lestem, S. Carr, J. Liu.
The effects of maternal depression on fetal heart rate response to vibroacoustic stimulation.
Dev Neuropsychol, 20 (2001), pp. 639-651
[21.]
H.I. Kaplan, B.J. Sadock, J.A. Grebb.
Synopsis of psychiatry.
Williams & Wilkins, (1994),
[22.]
D.J. Newport, A. Hostetter, A. Arnold, Z.N. Stowe.
The treatment of postpartum depression: minimizing infant exposures.
J Clin Psychiatry, 63 (2002), pp. 31-44
[23.]
C.T. Beck.
Postpartum depression: a metasynthesis.
Qual Health Res, 12 (2002), pp. 453-472
[24.]
V. Hendrick, L.M. Smith, S. Hwang, L.L. Altshuler, D. Haynes.
Weight gain in breastfed infants of mothers taking antidepressant medications.
J Clin Psychiatry, 64 (2003), pp. 410-413
[25.]
C. Hammen, P.A. Brennan.
Severity, chronicity, and timing of maternal depression and risk for adolescent offspring diagnoses in a community sample.
Arch Gen Psychiatry, 60 (2003), pp. 253-258
[26.]
Reuters Health Information. Glaxo to drop non-addictive Seroxat claim. 2003. Disponible en: http://www.medscape.com/viewarticle/4535219
[27.]
K.L. Wisner, J.M. Perel, R.L. Findling.
Antidepressant treatment during breast-feeding.
Am J Psychiatry, 153 (1996), pp. 1132-1137
[28.]
Statement Policy.
Use of psychoactive medication during pregnancy and possible effects on the fetus and newborn (RE9866).
Pediatrics, 105 (2000), pp. 880-887
[29.]
G.E. Simon, M.L. Cunningham, R.L. Davis.
Outcomes of prenatal antidepressant exposure.
Am J Psychiatry, 159 (2002), pp. 2055-2061
[30.]
T. Heikkinen, U. Ekblad, P. Kero, S. Ekblad, K. Laine.
Citalopram in pregnancy and lactation.
Clin Pharmacol Ther, 72 (2002), pp. 184-191
[31.]
A. Ericson, B. Källén, B. Wiholm.
Pharmacodynamics: delivery outcome after the use of antidepressants in early pregnancy.
Eur J Clin Pharmacology, 155 (1999), pp. 503-508
[32.]
H. Nordeng, R. Lindemann, K.V. Perminov, A. Reikvam.
Neonatal withdrawal syndrome after in utero exposure to selective serotonin reuptake inhibitors.
Acta Paediatr, 90 (2001), pp. 288-291
[33.]
J.L. Morrison, C. Chien, K.W. Riggs, N. Gruber, D. Rurak.
Effect of maternal fluoxetine administration on uterine flow, blood fetal blood status gas, and growth.
Pediatr Res, 51 (2002), pp. 433-442
[34.]
C. Chilvers, M. Dewey, K. Fielding, V. Gretton, P. Miller, B. Palmer, et al.
Antidepressant drugs and generic counselling for treatment of major depression in primary care: randomised trial with patient preference arms.
Bmj, 322 (2001), pp. 772
[35.]
E. Ward, M. King, M. Lloyd, P. Bower, B. Sibbald, S. Farrelly, et al.
Randomised controlled trial of non-directive counselling cognitive-behaviour therapy, and usual general practitioner care for patients with depression. I. Clinical effectiveness.
Bmj, 321 (2000), pp. 1383-1388
[36.]
R. Nonacs, L.S. Cohen.
Depression during pregnancy: diagnosis and treatment options.
J Clin Psychiatry, 63 (2002), pp. 24-30
[37.]
D.A. Oren, K.L. Wisner, M. Spinelli, C.N. Epperson, K.S. Peindl, T.S. Terman, et al.
An open trial of morning light therapy for treatment of antepartum depression.
Am J Psychiatry, 159 (2002), pp. 666-669
[38.]
H. Tiemeier, H. Ruud van Tuijl, A. Hofman, J. Meijer, A.J. Kiliaan, M.M.B. Breteler.
Vitamin B12, folate and homocysteine in depression: the Rotterdam Study.
Am J Psychiatry, 159 (2002), pp. 2099-2101
[39.]
F. Dimeo, M. Bauer, I. Varahram, G. Proest, U. Halter.
Benefits from aerobic exercise in patients with major depression: a pilot study.
Br J Sports Med, 35 (2001), pp. 114-117
[40.]
D.A. Lawlor, S.W. Hopker.
The effectiveness of exercise as an intervention in the management of depression: systematic review and meta-regression analysis of randomized controlled trials.
Bmj, 322 (2001), pp. 763-766
[41.]
E. Ernst.
The risk-benefit profile of commonly used herbal therapies.
Ann Intern Med, 136 (2002), pp. 44-46
[42.]
H. Woelk, M. Beneke, I. Gebert, F. Rappard, H. Rechziegler.
Hypericum extract ZE 117: an open long-term study in patients with mild-moderate depression.
Phytomedicine, 109 (2000), pp. 115
[43.]
R.C. Shelton, M.B. Keller, A. Gelenberg, D.L. Dunner, R. Hirschfeld, M.E. Thase, et al.
Effectiveness of St John’s wort in major depression.
Jama, 285 (2001), pp. 18
[44.]
S.M. Turton-Weeks, G.W. Barone, B.J. Gurley, B.L. Ketel, M.L. Lightfoot, S.R. Abul-Ezz.
St John’s wort: a hidden risk for transplant patients.
Prog Transplant, 11 (2001), pp. 116-120
[45.]
St. John’s Wort may weaken effectiveness of oral contraceptives.
Reuters Health Information.
(2002),
[46.]
G.K. Dresser.
Chairman’s introduction. Annual Meeting of the American Society of Clinical Pharmacology Therapeutics.
Orlando, (2001),
[47.]
P.J. Cooper, L. Murray, A. Wilson, H. Romaniuk.
Controlled trial of the short-and long-term effect of psychological treatment of post-partum depression.
Br J Psychiatry, 182 (2003), pp. 412-419
[48.]
Agency for Healthcare Research and Quality.
Chairman’s statements: recommendations and rationale screening for depression.
Mental Health Weekly, 12 (2002), pp. 5
[49.]
J.L. Cox, J.M. Holden, R. Sagovsky.
Detection of postnatal depression: development of the 10-item Edinburgh Postnatal Depression Scale.
Br J Psychiatry, 150 (1997), pp. 782-876
[50.]
S.S. Fergerson, D.J. Jamieson, M. Lindsay.
Diagnosing postpartum depression: Can we do better?.
Am J Obstet Gynecol, 186 (2002), pp. 899-902
Copyright © 2004. Sociedad Española de Ginecología y Obstetricia
Descargar PDF
Opciones de artículo
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos